Arrowhead Pharmaceuticals (ARWR) FCF Margin (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted FCF Margin of 111.04% for Q1 2026, up 2486.96% on a QoQ basis from 4.29% in Q4 2025, and up 2816.0% year-over-year from 3.81% in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) FCF Margin (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' FCF Margin history runs 17 years deep, the most recent figure standing at 111.04% for Q1 2026.
- Quarterly FCF Margin rose 2816.0% year-over-year to 111.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.58% (down 634.0% YoY) and the FY2025 annual result came in at 21.61%, up 1703992.0% from the prior year.
- FCF Margin was 111.04% for Q1 2026 at Arrowhead Pharmaceuticals, up from 4.29% in the prior quarter.
- Across five years, FCF Margin topped out at 188.46% in Q2 2023 and bottomed at 5953.84% in Q4 2024.
- A 5-year average of 945.25% and a median of 111.64% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin sank 506898 bps — and 2025, when it soared 595813 bps.
- Arrowhead Pharmaceuticals' FCF Margin stood at 182.95% in 2022, then tumbled by 2771 bps to 5251.93% in 2023, then fell by 13 bps to 5953.84% in 2024, then soared by 100 bps to 4.29% in 2025, then surged by 2487 bps to 111.04% in 2026.
- Business Quant data shows ARWR's FCF Margin at 111.04% in Q1 2026, 4.29% in Q4 2025, and 8.02% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - | 111.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 111.04% |
| Dec 31, 2025 | 4.29% |
| Sep 30, 2025 | 8.02% |
| Jun 30, 2025 | -512.31% |
| Mar 31, 2025 | 82.88% |
| Dec 31, 2024 | -5,953.84% |
| Dec 31, 2023 | -5,251.93% |
| Sep 30, 2023 | -1,161.95% |
| Jun 30, 2023 | 188.46% |
| Mar 31, 2023 | -40.33% |
| Dec 31, 2022 | -182.95% |
| Sep 30, 2022 | -321.29% |
| Jun 30, 2022 | -241.73% |
| Mar 31, 2022 | 38.19% |
| Dec 31, 2021 | -244.49% |
| Sep 30, 2021 | -84.18% |
| Jun 30, 2021 | -73.09% |
| Mar 31, 2021 | 782.38% |
| Dec 31, 2020 | -202.76% |
| Sep 30, 2020 | -172.22% |